Biocon Wants 1 In 5 Insulin Users Worldwide On Its Products And A Market In Transition Is Helping

As big insulin makers pivot to GLP-1 blockbusters and exit the space, Biocon’s Kiran Mazumdar Shaw sees a rare opening to become the world’s dominant insulin company